Cargando…

Comorbidities in patients with Unverricht–Lundborg disease (EPM1)

BACKGROUND: Unverricht‐Lundborg disease (EPM1) typically leads to accumulating disability. Disability may also be caused by comorbidities but there are no data available on these. AIMS OF THE STUDY: To investigate the frequency of comorbidities in EPM1. METHODS: Comorbidity data of a previously desc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sipilä, Jussi O. T., Kälviäinen, Reetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826374/
https://www.ncbi.nlm.nih.gov/pubmed/36097839
http://dx.doi.org/10.1111/ane.13706
_version_ 1784866835550699520
author Sipilä, Jussi O. T.
Kälviäinen, Reetta
author_facet Sipilä, Jussi O. T.
Kälviäinen, Reetta
author_sort Sipilä, Jussi O. T.
collection PubMed
description BACKGROUND: Unverricht‐Lundborg disease (EPM1) typically leads to accumulating disability. Disability may also be caused by comorbidities but there are no data available on these. AIMS OF THE STUDY: To investigate the frequency of comorbidities in EPM1. METHODS: Comorbidity data of a previously described cohort of 135 Finnish patients with EPM1 were retrieved from neurological, surgical (including subspecialities), internal medicine (including subspecialities) and intensive care patient charts of the treating hospitals. RESULTS: Mean follow‐up time was 31.4 years (SD 12.4 years, range 6.8–57.8 years), during which at least one comorbidity was observed in 107 patients (79%) and three or more in 53 (39%). The most common diagnostic categories were external injuries, mental and behavioural disorders and endocrine, nutritional and metabolic diseases. The most common single comorbid diagnosis was a fracture of the ankle (in 19% of all patients). The second most common single comorbid diagnosis in the cohort was diabetes (in 13% of all patients), and the third was depression, recorded for 13% of the cohort. Malignancies and cardiovascular end‐organ damage were rare, whereas phimosis/paraphimosis appeared more common than in general population. CONCLUSIONS: Patients with EPM1 often have comorbidities. Trauma and mental health risks should be especially followed and acted upon. Further studies are needed to more accurately comorbidity risks, characteristics and patient needs.
format Online
Article
Text
id pubmed-9826374
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98263742023-01-09 Comorbidities in patients with Unverricht–Lundborg disease (EPM1) Sipilä, Jussi O. T. Kälviäinen, Reetta Acta Neurol Scand Clinical Commentary BACKGROUND: Unverricht‐Lundborg disease (EPM1) typically leads to accumulating disability. Disability may also be caused by comorbidities but there are no data available on these. AIMS OF THE STUDY: To investigate the frequency of comorbidities in EPM1. METHODS: Comorbidity data of a previously described cohort of 135 Finnish patients with EPM1 were retrieved from neurological, surgical (including subspecialities), internal medicine (including subspecialities) and intensive care patient charts of the treating hospitals. RESULTS: Mean follow‐up time was 31.4 years (SD 12.4 years, range 6.8–57.8 years), during which at least one comorbidity was observed in 107 patients (79%) and three or more in 53 (39%). The most common diagnostic categories were external injuries, mental and behavioural disorders and endocrine, nutritional and metabolic diseases. The most common single comorbid diagnosis was a fracture of the ankle (in 19% of all patients). The second most common single comorbid diagnosis in the cohort was diabetes (in 13% of all patients), and the third was depression, recorded for 13% of the cohort. Malignancies and cardiovascular end‐organ damage were rare, whereas phimosis/paraphimosis appeared more common than in general population. CONCLUSIONS: Patients with EPM1 often have comorbidities. Trauma and mental health risks should be especially followed and acted upon. Further studies are needed to more accurately comorbidity risks, characteristics and patient needs. John Wiley and Sons Inc. 2022-09-13 2022-11 /pmc/articles/PMC9826374/ /pubmed/36097839 http://dx.doi.org/10.1111/ane.13706 Text en © 2022 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Clinical Commentary
Sipilä, Jussi O. T.
Kälviäinen, Reetta
Comorbidities in patients with Unverricht–Lundborg disease (EPM1)
title Comorbidities in patients with Unverricht–Lundborg disease (EPM1)
title_full Comorbidities in patients with Unverricht–Lundborg disease (EPM1)
title_fullStr Comorbidities in patients with Unverricht–Lundborg disease (EPM1)
title_full_unstemmed Comorbidities in patients with Unverricht–Lundborg disease (EPM1)
title_short Comorbidities in patients with Unverricht–Lundborg disease (EPM1)
title_sort comorbidities in patients with unverricht–lundborg disease (epm1)
topic Clinical Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826374/
https://www.ncbi.nlm.nih.gov/pubmed/36097839
http://dx.doi.org/10.1111/ane.13706
work_keys_str_mv AT sipilajussiot comorbiditiesinpatientswithunverrichtlundborgdiseaseepm1
AT kalviainenreetta comorbiditiesinpatientswithunverrichtlundborgdiseaseepm1